200,000+ products from a single source!
sales@angenechem.com
160003-66-7 | Benzamide, 4-iodo-3-nitro-
CAS No: 160003-66-7 Catalog No: AG001RLR MDL No:MFCD11110639
Product Description
Catalog Number:
AG001RLR
Chemical Name:
Benzamide, 4-iodo-3-nitro-
CAS Number:
160003-66-7
Molecular Formula:
C7H5IN2O3
Molecular Weight:
292.0307
MDL Number:
MFCD11110639
IUPAC Name:
4-iodo-3-nitrobenzamide
InChI:
InChI=1S/C7H5IN2O3/c8-5-2-1-4(7(9)11)3-6(5)10(12)13/h1-3H,(H2,9,11)
InChI Key:
MDOJTZQKHMAPBK-UHFFFAOYSA-N
SMILES:
[O-][N+](=O)c1cc(ccc1I)C(=O)N
UNII:
2ZWI7KHK8F
Properties
Complexity:
228
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
291.934g/mol
Formal Charge:
0
Heavy Atom Count:
13
Hydrogen Bond Acceptor Count:
3
Hydrogen Bond Donor Count:
1
Isotope Atom Count:
0
Molecular Weight:
292.032g/mol
Monoisotopic Mass:
291.934g/mol
Rotatable Bond Count:
1
Topological Polar Surface Area:
88.9A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
1.3
Literature
| Title | Journal |
|---|---|
| Pharmacological Inhibition of poly(ADP-ribose) polymerases improves fitness and mitochondrial function in skeletal muscle. | Cell metabolism 20140603 |
| Identification of potent Yes1 kinase inhibitors using a library screening approach. | Bioorganic & medicinal chemistry letters 20130801 |
| Iniparib plus paclitaxel and carboplatin as initial treatment of advanced or recurrent uterine carcinosarcoma: a Gynecologic Oncology Group Study. | Gynecologic oncology 20120901 |
| Neoadjuvant treatments for triple-negative breast cancer (TNBC). | Annals of oncology : official journal of the European Society for Medical Oncology 20120801 |
| Current and emerging targeted therapies for metastatic breast cancer. | Cancer 20120615 |
| Dissecting the heterogeneity of triple-negative breast cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120520 |
| Re: potential pitfalls of crossover and thoughts on iniparib in triple-negative breast cancer. | Journal of the National Cancer Institute 20120502 |
| Nickel-catalysed aromatic Finkelstein reaction of aryl and heteroaryl bromides. | Chemical communications (Cambridge, England) 20120425 |
| [PARP inhibitors and breast cancer: update and perspectives]. | Bulletin du cancer 20120401 |
| Drug candidates derailed in case of mistaken identity. | Nature 20120328 |
| Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro. | Clinical cancer research : an official journal of the American Association for Cancer Research 20120315 |
| Present status and problems on molecular targeted therapy of cancer. | Cancer research and treatment : official journal of Korean Cancer Association 20120301 |
| Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor. | Clinical cancer research : an official journal of the American Association for Cancer Research 20120115 |
| Basal breast cancer: a complex and deadly molecular subtype. | Current molecular medicine 20120101 |
| Ovarian cancer: opportunity for targeted therapy. | Journal of oncology 20120101 |
| BRCAness profile of sporadic ovarian cancer predicts disease recurrence. | PloS one 20120101 |
| Molecular basis of triple negative breast cancer and implications for therapy. | International journal of breast cancer 20120101 |
| Current Status of Poly(ADP-ribose) Polymerase Inhibitors as Novel Therapeutic Agents for Triple-Negative Breast Cancer. | International journal of breast cancer 20120101 |
| Major clinical research advances in gynecologic cancer in 2011. | Journal of gynecologic oncology 20120101 |
| Advances in using PARP inhibitors to treat cancer. | BMC medicine 20120101 |
| Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways. | Journal of oncology 20120101 |
| Metastasis of neuroendocrine tumors are characterized by increased cell proliferation and reduced expression of the ATM gene. | PloS one 20120101 |
| Advancements in the Treatment of Metastatic Breast Cancer (MBC): The Role of Ixabepilone. | Journal of oncology 20120101 |
| The first European interdisciplinary ewing sarcoma research summit. | Frontiers in oncology 20120101 |
| Potential pitfalls of crossover and thoughts on iniparib in triple-negative breast cancer. | Journal of the National Cancer Institute 20111207 |
| The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy. | Therapeutic advances in medical oncology 20111101 |
| Response of subtype-specific human breast cancer-derived cells to poly(ADP-ribose) polymerase and checkpoint kinase 1 inhibition. | Cancer science 20111001 |
| PARP inhibitors--current status and the walk towards early breast cancer. | Breast (Edinburgh, Scotland) 20111001 |
| DNA-damaging therapies emerging as possible triple-negative breast cancer therapies. | Oncology (Williston Park, N.Y.) 20111001 |
| PARP inhibitors: its role in treatment of cancer. | Chinese journal of cancer 20110701 |
| Novel agents and future directions for refractory breast cancer. | Seminars in oncology 20110601 |
| Iniparib in metastatic triple-negative breast cancer. | The New England journal of medicine 20110505 |
| Few positives for triple-negative breast cancer. | Journal of the National Cancer Institute 20110406 |
| Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer. | Anticancer research 20110401 |
| Triple negative breast cancer: unmet medical needs. | Breast cancer research and treatment 20110201 |
| Iniparib plus chemotherapy in metastatic triple-negative breast cancer. | The New England journal of medicine 20110120 |
| PARP and cancer--if it's broke, don't fix it. | The New England journal of medicine 20110120 |
| PARP inhibitors in oncology: a new synthetic lethal approach to cancer therapy. | Acta clinica Belgica 20110101 |
| Promising molecular targeted therapies in breast cancer. | Indian journal of pharmacology 20110101 |
| Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies. | Cancer management and research 20110101 |
| Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells. | BMC pharmacology 20110101 |
| Drug therapy for hereditary cancers. | Hereditary cancer in clinical practice 20110101 |
| Management options in triple-negative breast cancer. | Breast cancer : basic and clinical research 20110101 |
| Poly(ADP-ribose) polymerase inhibition: a new direction for BRCA and triple-negative breast cancer? | Breast cancer research : BCR 20110101 |
| Tips and tricks in triple-negative breast cancer: how to manage patients in real-life practice? | Ecancermedicalscience 20110101 |
| Triple-negative breast cancer: adjuvant therapeutic options. | Chemotherapy research and practice 20110101 |
| [PARP inhibitors to treat triple negative breast cancer]. | Gan to kagaku ryoho. Cancer & chemotherapy 20101201 |
| Iniparib, a PARP1 inhibitor for the potential treatment of cancer, including triple-negative breast cancer. | IDrugs : the investigational drugs journal 20100901 |
| Small-molecule PARP modulators--current status and future therapeutic potential. | Current opinion in drug discovery & development 20100901 |
| Beyond PARP inhibitors: agents in pipelines target DNA repair mechanisms. | Journal of the National Cancer Institute 20100804 |
| Treatment options for patients with triple-negative breast cancer. | Journal of hematology & oncology 20100101 |
| Directed therapy of subtypes of triple-negative breast cancer. | The oncologist 20100101 |
| Enzymatic mechanism of the tumoricidal action of 4-iodo-3-nitrobenzamide. | Molecular medicine reports 20090101 |
| Anti-cancer action of 4-iodo-3-nitrobenzamide in combination with buthionine sulfoximine: inactivation of poly(ADP-ribose) polymerase and tumor glycolysis and the appearance of a poly(ADP-ribose) polymerase protease. | Biochemical pharmacology 20020201 |
| Potential chemotherapeutic activity of 4-iodo-3-nitrobenzamide. Metabolic reduction to the 3-nitroso derivative and induction of cell death in tumor cells in culture. | Biochemical pharmacology 19950825 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.